Corvus Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of agents, which target the immune system to treat patients with cancer. The Company is developing drugs and antibodies that block crucial immune checkpoints, and reprogram immune T-cells. Its products include CPI-444, Adenosine production inhibitor (a monoclonal anti-CD73 antibody), Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. CPI-444 is an orally administered antagonist of the adenosine A2A receptor, which is designed to block the action of adenosine that is produced by tumors. Its anti-CD73 monoclonal antibody binds to the enzyme cluster of differentiation 73 (CD73) and has been shown to block its catalytic activity, inhibiting adenosine production by tumor cells. It is also developing orally administered and covalent inhibitors of ITK.